PR Newswire
STANS, Switzerland , June 2, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer , Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview at the LD Micro Virtual Invitational Conference being held on
June 8 – June 10 , 2021.
Mr. Zwyer will deliver his corporate presentation on June 10 at 11:30am ET , Track 2 and the presentation can be viewed here . Investors attending the conference and interested in scheduling a meeting with management should contact assistant@ldmicro.com .
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience ® is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.
Corporate Contact
Alex Zwyer , CEO: +41 41 618 80 00
Investor Relations Contact
Cindy Rizzo : +1 908-229-7050
SOURCE NEUROLIFESCIENCES